Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
Addict Biol ; 22(5): 1232-1245, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-27212105

RESUMEN

Morphine is one of the most effective drugs used for pain management, but it is also highly addictive. Morphine elicits acute and long-term adaptive changes at cellular and molecular level in the brain, which play a critical role in the development of tolerance, dependence and addiction. Previous studies indicated that the dopamine D4 receptor (D4 R) activation counteracts morphine-induced adaptive changes of the µ opioid receptor (MOR) signaling in the striosomes of the caudate putamen (CPu), as well as the induction of several Fos family transcription factors. Thus, it has been suggested that D4 R could play an important role avoiding some of the addictive effects of morphine. Here, using different drugs administration paradigms, it is determined that the D4 R agonist PD168,077 prevents morphine-induced activation of the nigrostriatal dopamine pathway and morphological changes of substantia nigra pars compacta (SNc) dopamine neurons, leading to a restoration of dopamine levels and metabolism in the CPu. Results from receptor autoradiography indicate that D4 R activation modulates MOR function in the substantia nigra pars reticulata (SNr) and the striosomes of the CPu, suggesting that these regions are critically involved in the modulation of SNc dopamine neuronal function through a functional D4 R/MOR interaction. In addition, D4 R activation counteracts the rewarding effects of morphine, as well as the development of hyperlocomotion and physical dependence without any effect on its analgesic properties. These results provide a novel role of D4 R agonist as a pharmacological strategy to prevent the adverse effects of morphine in the treatment of pain.


Asunto(s)
Analgésicos Opioides/farmacología , Benzamidas/farmacología , Agonistas de Dopamina/farmacología , Morfina/farmacología , Neostriado/efectos de los fármacos , Piperazinas/farmacología , Receptores de Dopamina D4/agonistas , Recompensa , Sustancia Negra/efectos de los fármacos , Animales , Autorradiografía , Núcleo Caudado/efectos de los fármacos , Núcleo Caudado/metabolismo , Tolerancia a Medicamentos , Masculino , Neostriado/metabolismo , Porción Compacta de la Sustancia Negra/efectos de los fármacos , Porción Compacta de la Sustancia Negra/metabolismo , Porción Reticular de la Sustancia Negra/efectos de los fármacos , Porción Reticular de la Sustancia Negra/metabolismo , Putamen/efectos de los fármacos , Putamen/metabolismo , Ratas , Ratas Sprague-Dawley , Receptores de Dopamina D4/metabolismo , Receptores Opioides mu/metabolismo , Trastornos Relacionados con Sustancias/metabolismo , Sustancia Negra/metabolismo
2.
Int J Mol Sci ; 15(1): 1481-98, 2014 Jan 21.
Artículo en Inglés | MEDLINE | ID: mdl-24451133

RESUMEN

The mu opioid receptor (MOR) is critical in mediating morphine analgesia. However, prolonged exposure to morphine induces adaptive changes in this receptor leading to the development of tolerance and addiction. In the present work we have studied whether the continuous administration of morphine induces changes in MOR protein levels, its pharmacological profile, and MOR-mediated G-protein activation in the striosomal compartment of the rat CPu, by using immunohistochemistry and receptor and DAMGO-stimulated [35S]GTPγS autoradiography. MOR immunoreactivity, agonist binding density and its coupling to G proteins are up-regulated in the striosomes by continuous morphine treatment in the absence of changes in enkephalin and dynorphin mRNA levels. In addition, co-treatment of morphine with the dopamine D4 receptor (D4R) agonist PD168,077 fully counteracts these adaptive changes in MOR, in spite of the fact that continuous PD168,077 treatment increases the [3H]DAMGO Bmax values to the same degree as seen after continuous morphine treatment. Thus, in spite of the fact that both receptors can be coupled to Gi/0 protein, the present results give support for the existence of antagonistic functional D4R-MOR receptor-receptor interactions in the adaptive changes occurring in MOR of striosomes on continuous administration of morphine.


Asunto(s)
Morfina/farmacología , Putamen/metabolismo , Receptores de Dopamina D4/metabolismo , Receptores Opioides mu/metabolismo , Transducción de Señal , Adaptación Fisiológica , Animales , Agonistas de Dopamina/farmacología , Dinorfinas/genética , Dinorfinas/metabolismo , Encefalinas/genética , Encefalinas/metabolismo , Masculino , Putamen/efectos de los fármacos , ARN Mensajero/genética , ARN Mensajero/metabolismo , Ratas , Ratas Sprague-Dawley , Receptores de Dopamina D4/agonistas , Receptores Opioides mu/genética
3.
J Neurosci Res ; 91(12): 1533-40, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24038231

RESUMEN

The peptides dynorphin and enkephalin modulate many physiological processes, such as motor activity and the control of mood and motivation. Their expression in the caudate putamen (CPu) is regulated by dopamine and opioid receptors. The current work was designed to explore the early effects of the acute activation of D4 and/or µ opioid receptors by the agonists PD168,077 and morphine, respectively, on the regulation of the expression of these opioid peptides in the rat CPu, on transcription factors linked to them, and on the expression of µ opioid receptors. In situ hybridization experiments showed that acute treatment with morphine (10 mg/kg) decreased both enkephalin and dynorphin mRNA levels in the CPu after 30 min, but PD168,077 (1 mg/kg) did not modify their expression. Coadministration of the two agonists demonstrated that PD168,077 counteracted the morphine-induced changes and even increased enkephalin mRNA levels. The immunohistochemistry studies showed that morphine administration also increased striatal µ opioid receptor immunoreactivity but reduced P-CREB expression, effects that were blocked by the PD168,077-induced activation of D4 receptors. The current results present evidence of functional D4 -µ opioid receptor interactions, with consequences for the opioid peptide mRNA levels in the rat CPu, contributing to the integration of DA and opioid peptide signaling.


Asunto(s)
Analgésicos Opioides/farmacología , Morfina/farmacología , Péptidos Opioides/biosíntesis , Putamen/metabolismo , Receptores de Dopamina D4/metabolismo , Animales , Dinorfinas/biosíntesis , Encefalinas/biosíntesis , Inmunohistoquímica , Hibridación in Situ , Masculino , Putamen/efectos de los fármacos , ARN Mensajero/análisis , Ratas , Ratas Sprague-Dawley , Receptores Opioides mu/metabolismo
4.
J Comp Neurol ; 502(3): 358-66, 2007 May 20.
Artículo en Inglés | MEDLINE | ID: mdl-17366605

RESUMEN

The dopaminergic and opioid peptide systems interact in many nuclei of the brain. In the striatum, dopamine/opioid peptide interactions modulate locomotor and motivated behaviors as well as reward, motivational, and tolerance processes in opiate dependence. Dopamine D(4) receptors (D(4) R) and mu-opioid receptors (MOR) are highly concentrated in the striosomes (islands) of the striatum, suggesting the existence of receptor-receptor interactions between them. In the present work we studied the role of D(4) R in modulating MOR expression in the islands by using immunohistochemistry and image analysis. The activation of D(4) R by the agonist PD168,077 (1 mg/kg) decreased MOR immunoreactivity (IR) in the striosomes 6 hours after drug treatment. MOR IR levels had recovered 12 hours later. Treatment with a D(4) R antagonist (L745,870, 1mg/kg) blocked downregulation of MOR IR, showing that the D(4) R agonist effects observed were specific. Furthermore, treatment with the D(2)/D(3) receptor agonist quinpirol (1 mg/kg) and D(2)/D(3) receptor antagonist raclopride (1 mg/kg) had no effect in MOR IR, suggesting that D(4) R is the only D2-like receptor producing an MOR downregulation in the islands. The decreases of MOR IR in the striosomes suggest that D(4) R activation may reduce MOR signaling. Increasing evidence has demonstrated that the islands in the striatum play a critical role in habit acquisition during drug addiction. D(4) R/MOR interactions could be crucial in such processes.


Asunto(s)
Cuerpo Estriado/metabolismo , Regulación de la Expresión Génica/fisiología , Receptores de Dopamina D4/metabolismo , Receptores Opioides mu/metabolismo , Animales , Benzamidas/farmacología , Agonistas de Dopamina/farmacología , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Regulación de la Expresión Génica/efectos de los fármacos , Masculino , Piperazinas/farmacología , Piridinas/farmacología , Pirroles/farmacología , Ratas , Ratas Sprague-Dawley , Factores de Tiempo
5.
J Neurosci ; 23(3): 816-25, 2003 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-12574410

RESUMEN

Dopamine is a crucial factor in basal ganglia functioning. In current models of basal ganglia, dopamine is postulated to act on striatal neurons. However, it may also act on the subthalamic nucleus (STN), a key nucleus in the basal ganglia circuit. The data presented here were obtained in brain slices using whole-cell patch clamp. They reveal that D5 dopamine receptors strengthen electrical activity in the subset of subthalamic neurons endowed with burst-firing capacity, resulting in longer discharges of spontaneous or evoked bursts. To distinguish between D1 and D5 subtypes, the action of agonists in the D1/D5 receptor family was first investigated on rat subthalamic neurons. Single-cell reverse transcription-PCR profiling showed that burst-competent neurons only expressed D5 receptors. Accordingly, receptors localized in postsynaptic membranes within the STN were labeled by a D5-specific antibody. Second, agonists in the D1/D5 family were tested in mouse brain slices. It was found that these agonists were active in D1 receptor knock-out mice in a similar way to wild-type mice or rats. This proved that D5 rather than D1 receptors were involved. Pharmacological tools (dihydropyridines, omega-conotoxins, and calciseptine) were used to identify the target of D5 receptors as an L-type channel. This was reached via G-protein and protein kinase A. The action of dopamine on D5 receptors therefore shapes neuronal activity. It contributes to normal information processing in basal ganglia outside striatum. This finding may be useful in drug therapy for various disorders involving changes in STN activity, such as Parkinson's disease and related disorders.


Asunto(s)
Canales de Calcio Tipo L/metabolismo , Neuronas/fisiología , Receptores de Dopamina D1/metabolismo , Núcleo Subtalámico/fisiología , Transmisión Sináptica/fisiología , Animales , Bloqueadores de los Canales de Calcio/farmacología , Canales de Calcio Tipo L/efectos de los fármacos , Proteínas Quinasas Dependientes de AMP Cíclico/metabolismo , Agonistas de Dopamina/farmacología , Inhibidores Enzimáticos/farmacología , Agonistas de Aminoácidos Excitadores/farmacología , Proteínas de Unión al GTP/metabolismo , Técnicas In Vitro , Potenciales de la Membrana/fisiología , Ratones , Ratones Noqueados , Neuronas/metabolismo , Técnicas de Placa-Clamp , Bloqueadores de los Canales de Potasio/farmacología , Ratas , Ratas Wistar , Receptores de Dopamina D1/agonistas , Receptores de Dopamina D1/deficiencia , Receptores de Dopamina D1/genética , Receptores de Dopamina D5 , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología , Núcleo Subtalámico/citología , Núcleo Subtalámico/metabolismo , Transmisión Sináptica/efectos de los fármacos
6.
Brain Res ; 989(1): 35-41, 2003 Oct 31.
Artículo en Inglés | MEDLINE | ID: mdl-14519509

RESUMEN

Recent studies have reported the regional distribution of D(4) dopamine receptors in the rat striatum at the cellular and subcellular levels. However, the precise identity of the striatal neurons that express these receptors remains unknown. We have studied the expression of D(4) receptors in the striatal interneurons as well as in the output regions of the striatum using immunohistochemistry. Furthermore, we have evaluated the contribution of the striatum to D(4) receptor immunoreactivity in these areas by means of ibotenic acid lesion of the striatum. D(4) receptors were observed in the substantia nigra pars reticulata (SNr), the entopeduncular nucleus (EP) and the globus pallidus (GP), and they were found, using electron microscopy, to be located presynaptically. D(4) immunoreactivity in the striatal output nuclei was observed to dramatically decrease following lesion of the striatum with ibotenic acid. Striatal interneurons were not found to express D(4) receptors. These results demonstrate that D(4) receptors are located almost exclusively in striatal projection neurons, in both striatonigral and striatopallidal neurons.


Asunto(s)
Cuerpo Estriado/metabolismo , Globo Pálido/metabolismo , Neuronas/metabolismo , Receptores de Dopamina D2/biosíntesis , Sustancia Negra/metabolismo , Animales , Cuerpo Estriado/ultraestructura , Regulación de la Expresión Génica/fisiología , Globo Pálido/ultraestructura , Masculino , Neuronas/ultraestructura , Ratas , Ratas Wistar , Receptores de Dopamina D2/genética , Receptores de Dopamina D2/ultraestructura , Receptores de Dopamina D4 , Sustancia Negra/ultraestructura
7.
Artículo en Inglés | MEDLINE | ID: mdl-14751419

RESUMEN

3,4-Methylenedioxymethamphetamine (MDMA) is a synthetic amphetamine popularly known as "Ecstasy." Animal studies examining acute effects of MDMA on anxiety are unclear because although an anxiolytic-like action of MDMA in different animal models of anxiety has been described, there is also substantial evidence supporting an anxiogenic-like effect of this drug. To date, several studies have examined c-fos expression following MDMA administration in rats. However, there is no information about the MDMA-induced c-fos expression in mice previously tested in an animal model of anxiety. In this study, male mice were injected with MDMA (1, 8 and 15 mg/kg ip) and assessed for changes on anxiety and for the expression of the immediate early gene c-fos in the amygdala (central, basolateral and basomedial). Anxiety was evaluated by the "social interaction test." Ten behavioral categories were recorded: body care, digging, nonsocial exploration, exploration from a distance, social investigation, threat, attack, avoidance/flee, defense/submission and immobility. As compared with the control group, mice treated with MDMA (all doses) showed a decrease in mean duration and total time spent in social investigation behaviors, whereas avoidance/flee behaviors were significantly increased after treatment with this compound (8 and 15 mg/kg). Likewise, a significant increase in c-fos expression was found in the basolateral (all doses) and central (15 mg/kg) amygdala after MDMA administration. Overall, these findings indicate that MDMA exhibits an anxiogenic-like profile in the social interaction test in mice, and that central and basolateral amygdala might be involved in these anxiogenic-like effects of the drug.


Asunto(s)
Amígdala del Cerebelo/efectos de los fármacos , Alucinógenos/farmacología , Relaciones Interpersonales , N-Metil-3,4-metilenodioxianfetamina/farmacología , Proteínas Proto-Oncogénicas c-fos/metabolismo , Amígdala del Cerebelo/metabolismo , Animales , Conducta Animal , Recuento de Células/métodos , Relación Dosis-Respuesta a Droga , Expresión Génica/efectos de los fármacos , Inmunohistoquímica/métodos , Masculino , Ratones , Estadísticas no Paramétricas
8.
Brain Res ; 1407: 47-61, 2011 Aug 17.
Artículo en Inglés | MEDLINE | ID: mdl-21782156

RESUMEN

Acute administration of the dopamine D(4) receptor (D(4)R) agonist PD168,077 induces a down-regulation of the µ opioid receptor (MOR) in the striosomal compartment of the rat caudate putamen (CPu), suggesting a striosomal D(4)R/MOR receptor interaction in line with their high co-distribution in this brain subregion. The present work was designed to explore if a D(4)R/MOR receptor interaction also occurs in the modulation of the expression pattern of several transcription factors in striatal subregions that play a central role in drug addiction. Thus, c-Fos, FosB/ΔFosB and P-CREB immunoreactive profiles were quantified in the rat CPu after either acute or continuous (6-day) administration of morphine and/or PD168,077. Acute and continuous administration of morphine induced different patterns of expression of these transcription factors, effects that were time-course and region dependent and fully blocked by PD168,077 co-administration. Moreover, this effect of the D(4)R agonist was counteracted by the D(4)R antagonist L745,870. Interestingly, at some time-points, combined treatment with morphine and PD168,077 substantially increased c-Fos, FosB/ΔFosB and P-CREB expression. The results of this study give indications for a general antagonistic D(4)R/MOR receptor interaction at the level of transcription factors. The change in the transcription factor expression by D(4)R/MOR interactions in turn suggests a modulation of neuronal activity in the CPu that could be of relevance for drug addiction.


Asunto(s)
Analgésicos Opioides/farmacología , Núcleo Caudado/metabolismo , Morfina/farmacología , Putamen/metabolismo , Receptores de Dopamina D4/efectos de los fármacos , Factores de Transcripción/biosíntesis , Animales , Autorradiografía , Benzamidas/farmacología , Núcleo Caudado/efectos de los fármacos , Proteína de Unión a Elemento de Respuesta al AMP Cíclico/biosíntesis , Agonistas de Dopamina/farmacología , Antagonistas de Dopamina/farmacología , Genes fos/efectos de los fármacos , Inmunohistoquímica , Hibridación in Situ , Masculino , Piperazinas/farmacología , Proteínas Proto-Oncogénicas c-fos/biosíntesis , Putamen/efectos de los fármacos , Piridinas/farmacología , Pirroles/farmacología , Ratas , Ratas Sprague-Dawley , Receptores de Dopamina D4/agonistas , Receptores de Dopamina D4/antagonistas & inhibidores
9.
Eur J Neurosci ; 24(2): 499-508, 2006 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16903855

RESUMEN

The interactions between neuropeptide Y (NPY), specifically through NPY Y(1) and Y(2) receptor subtypes, and galanin [GAL(1-29)] have been analysed at the cardiovascular level. The cardiovascular effects of intracisternal coinjections of GAL(1-29) with NPY or NPY Y(1) or Y(2) agonists, as well as quantitative receptor autoradiography of the binding characteristics of NPY Y(1) and Y(2) receptor subtypes in the nucleus of the solitary tract (NTS), in the presence or absence of GAL(1-29), have been investigated. The effects of coinjections of GAL(1-29) and the NPY Y(1) agonist on the expression of c-FOS immunoreactivity in the NTS were also studied. The coinjection of NPY with GAL(1-29) induced a significant vasopressor and tachycardic action with a maximum 40% increase (P < 0.001). The coinjection of the NPY Y(1) agonist and GAL(1-29) induced a similar increase in mean arterial pressure and heart rate as did NPY plus GAL(1-29), actions that were not observed with the NPY Y(2) agonist plus GAL(1-29). GAL(1-29), 3 nm, significantly and substantially (by approximately 40%) decreased NPY Y(1) agonist binding in the NTS. This effect was significantly blocked (P < 0.01) in the presence of the specific galanin antagonist M35. The NPY Y(2) agonist binding was not modified in the presence of GAL(1-29). At the c-FOS level, the coinjection of NPY Y(1) and GAL(1-29) significantly reduced the c-FOS-immunoreactive response induced by either of the two peptides. The present findings suggest the existence of a modulatory antagonistic effect of GAL(1-29) mediated via galanin receptors on the NPY Y(1) receptor subtype and its signalling within the NTS.


Asunto(s)
Sistema Nervioso Autónomo/metabolismo , Fenómenos Fisiológicos Cardiovasculares , Galanina/metabolismo , Neuropéptido Y/metabolismo , Receptores de Neuropéptido Y/metabolismo , Núcleo Solitario/metabolismo , Animales , Unión Competitiva/efectos de los fármacos , Unión Competitiva/fisiología , Presión Sanguínea/efectos de los fármacos , Presión Sanguínea/fisiología , Bradiquinina/análogos & derivados , Bradiquinina/farmacología , Sinergismo Farmacológico , Galanina/farmacología , Frecuencia Cardíaca/efectos de los fármacos , Frecuencia Cardíaca/fisiología , Inmunohistoquímica , Masculino , Vías Nerviosas/metabolismo , Neuropéptido Y/agonistas , Neuropéptido Y/análogos & derivados , Fragmentos de Péptidos/farmacología , Proteínas Proto-Oncogénicas c-fos/metabolismo , Ensayo de Unión Radioligante , Ratas , Ratas Sprague-Dawley , Receptores de Galanina/agonistas , Receptores de Galanina/metabolismo , Receptores de Neuropéptido Y/agonistas , Transmisión Sináptica/efectos de los fármacos , Transmisión Sináptica/fisiología , Regulación hacia Arriba/efectos de los fármacos , Regulación hacia Arriba/fisiología
10.
Eur J Neurosci ; 16(11): 2049-58, 2002 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-12473072

RESUMEN

Dopamine is one of the principal neurotransmitters in the basal ganglia, where it plays a critical role in motor control and cognitive function through its interactions with the specific dopamine receptors D1 to D5. Although the activities mediated by most dopamine receptor subtypes have already been determined, the role of the D5 receptor subtype in the basal ganglia has still not been established. Furthermore, it is often difficult to distinguish between dopamine D5 and D1 receptors as they are stimulated by the same ligands, and they have a similar molecular structure and pharmacology. In an effort to understand the differences between these two receptor subtypes, we have studied the distribution of neurons containing D5 receptors in the striatum, and their molecular phenotype. As a result, we show that the D5 receptor subtype is present in two different populations of striatal neurons, projection neurons and interneurons. Overall, the abundance of this receptor subtype in the striatum is low, particularly in striatal projection neurons of both the direct and indirect projection pathways. In contrast, the expression of D5 receptors in striatal interneurons (cholinergic, somatostatin- or parvalbumin-positive neurons) is high, while low to moderate expression was observed in calretinin-positive neurons. Our results demonstrate the presence of D5 receptors in all the striatal cell populations so far described, although at different intensities in each. The fact that a large number of striatal neurons express the D5 receptor subtype suggests that this receptor fulfils an important function in the process of integrating information in the striatum.


Asunto(s)
Dopamina/metabolismo , Neostriado/metabolismo , Vías Nerviosas/metabolismo , Neuronas/metabolismo , Receptores de Dopamina D1/metabolismo , Animales , Calbindina 2 , Gatos , Colina O-Acetiltransferasa/metabolismo , Inmunohistoquímica , Interneuronas/citología , Interneuronas/metabolismo , Masculino , Neostriado/citología , Neuronas/citología , Neuropéptido Y/metabolismo , Óxido Nítrico Sintasa/metabolismo , Parvalbúminas/metabolismo , Fenotipo , Ratas , Ratas Wistar , Receptores de Dopamina D5 , Proteína G de Unión al Calcio S100/metabolismo , Somatostatina/metabolismo , Transmisión Sináptica/fisiología , Ácido gamma-Aminobutírico/metabolismo
11.
J Neurochem ; 80(2): 219-29, 2002 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11902112

RESUMEN

Two important aspects of striatal function, exploratory behaviour and motor co-ordination, require the integrity of the dopamine D4 receptor subtype. These receptors are also implicated in the pathophysiology of certain neuropsychiatric disorders. However, the distribution of D4 receptors in the striatum has not yet been described and this situation impairs our understanding of the anatomical substrate in which D4 receptors function. We developed a D4 receptor-specific antibody that has permitted us to investigate the regional and cellular localization of the receptor in the neostriatum of the rat, mouse, cat and monkey. The subcellular distribution and the synaptic organization of this receptor were also determined in the rat striatum. We found moderate levels of D4 receptor expression in the caudoputamen and lower levels in the nucleus accumbens. These receptors were expressed in cell bodies and in the neuropil and were heterogeneously distributed among different striatal compartments, being more abundant in striosomes than in the matrix. At the subcellular level, the receptor immunoreactivity was mainly localized to dendritic shafts and spines. The prominent immunoreactivity observed in the striosomes indicates that integrative processes involved in D4-mediated limbic behaviours occurs through the striosomes rather than accumbens, whereas the motor behaviour is based in the striatal matrix.


Asunto(s)
Neostriado/química , Núcleo Accumbens/química , Receptores de Dopamina D2/análisis , Animales , Gatos , Haplorrinos , Inmunohistoquímica , Masculino , Ratones , Ratones Endogámicos , Microscopía Electrónica , Neostriado/citología , Neuronas/química , Neuronas/ultraestructura , Neurópilo/química , Neurópilo/ultraestructura , Núcleo Accumbens/citología , Ratas , Ratas Wistar , Receptores de Dopamina D4 , Especificidad de la Especie
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA